Evidence map›Paper›PMID 42273090›Full record

ArticleQuantitative imaging in medicine and surgery2026

Novel extended field-of-view reconstruction algorithms in computed tomography simulation for imaging and volumetric modulated arc therapy dosimetry.

Zun Piao, Guangyu Wang, Yixuan Wang, Ziquan Wei, Mengke Qi, Shouliang Ding, Honghu Song, Yunfei Feng, Lecheng Jia, Haoran Sun and 2 more

Abstract read
In one paragraph

Article in Quantitative imaging in medicine and surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Zun Piao *State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
Guangyu Wang *State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
Yixuan Wang *State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
Ziquan WeiResearch Cooperation Department, United Imaging Research Institute of Innovative Medical Equipment, Shenzhen, China.
Mengke QiState Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
Shouliang DingState Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
Honghu SongState Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
Yunfei FengState Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
Lecheng JiaResearch Cooperation Department, United Imaging Research Institute of Innovative Medical Equipment, Shenzhen, China.
Haoran SunState Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
Sijuan HuangState Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
Xiaoyan HuangState Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Accurate computed tomography (CT) reconstruction is essential for effective radiotherapy, particularly when the patient anatomy extends beyond the standard scanning field of view (sFOV). Extended-FOV algorithms address this challenge, but their performance in clinical CT simulations remains unclear. This study systematically evaluated two algorithms, the extended-FOV reconstruction algorithm (eFOV) and the deep learning-enhanced eFOV (AI-eFOV), on the uCT610 Sim system (United Imaging Healthcare), with CT image quality and volumetric modulated arc therapy (VMAT) dosimetric accuracy being the outcomes. Methods: A whole-body phantom simulated off-center displacements (5-20 cm) for extended FOV reconstruction. Isocentric CT images served as the ground truth for the assessment of geometric distortion, Hounsfield unit (HU) stability, and autocontouring accuracy. VMAT plans for the lung, chest wall, and liver were analyzed for dosimetric impact, and four patient cases provided clinical validation. Results: With increasing displacement, eFOV showed large HU deviations [root mean squared error (RMSE) 96 HU; maximum error 275 HU for bone and 293 HU for soft tissue], whereas AI-eFOV reduced errors (RMSE 81 HU; maximum 65 HU for bone and 25 HU for soft tissue; P<0.01) and achieved higher autocontouring accuracy (Dice ≥0.973 for AI-eFOV and ≥0.926 for eFOV). In VMAT plans, both algorithms achieved >96.66% gamma passing rates (3%/3 mm) within a 10-cm offset. At 20 cm, AI-eFOV maintained a rate above 93.37%, while eFOV dropped to 82.05% in hypofractionated plans using the flattening-filter-free high dose rate delivery mode. Clinical data further confirmed AI-eFOV's advantage in artifact suppression and tissue boundary delineation. Conclusions: Image distortion is determined by anatomy and lateral displacement beyond the sFOV. AI-eFOV provided superior image quality and dosimetric accuracy, especially beyond 70 cm and should be preferred for cases with large offsets.

Indexed as

computed tomography simulation (CT simulation)Extended field of view (eFOV)reconstruction accuracyvolumetric modulated arc therapy dosimetric accuracy (VMAT dosimetric accuracy)

Identifiers

PMID42273090
PMCPMC13247934

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.